The following is a summary of “Association between different proportions of crescents and the progression of IgA nephropathy ...

BioCity Biopharma has reported positive Phase II results for SC0062 in treating IgA nephropathy, showing up to a 48.3% ...

Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most ...

程虹教授：目前，肾科医生对SGLT2抑制剂的肾脏保护作用已经有越来越深的认识，在临床实践中，SGLT2抑制剂可能更多用于非糖尿病的CKD患者，且发挥了非常重要的作用，包括降低蛋白尿、延缓肾病进展。实际上，当RAS抑制剂和SGLT2抑制剂联用时，患者蛋白尿可显著下降 5 。此外，有些患者可能由于血压较低，使用RAS抑制剂会受限，临床可能会选择SGLT2抑制剂来降低蛋白尿，同样也观察到非常好的临床疗效 ...

The company’s recent financial position is robust, with substantial cash reserves and proceeds from a public offering expected to sustain operations through the potential approval and commercial ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Q3 2024 Earnings Call Transcript October 31, 2024 Travere Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...

G Camp, a startup incubation platform dedicated to bringing Taiwan's startups to the global stage, is leading eight exceptional Taiwanese startups to participate in Web Summit, Europe's largest and ...

Jade Biosciences, Inc., a privately held biotechnology company dedicated to developing best-in-class therapies for patients ...